• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.

    2/14/25 10:50:26 AM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTNM alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Contineum Therapeutics, Inc.

    (Name of Issuer)


    Class A Common Stock

    (Title of Class of Securities)


    21217B100

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    21217B100


    1Names of Reporting Persons

    Sectoral Asset Management Inc
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    800,787.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    800,787.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    800,787.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    21217B100


    1Names of Reporting Persons

    Jerome G. Pfund
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    SWITZERLAND
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    950,786.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    950,786.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    950,786.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Contineum Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    10578 Science Center Drive, Suite 200 San Diego, CA, 92121
    Item 2. 
    (a)Name of person filing:

    Jerome G. Pfund Sectoral Asset Management Inc.
    (b)Address or principal business office or, if none, residence:

    The principal business address of each of the Reporting Persons is 1610-1010 Sherbrooke St. West, Montreal QC, H3A 2R7 Canada
    (c)Citizenship:

    Jerome G. Pfund is a Swiss citizen Sectoral Asset Management Inc. is a Canadian corporation
    (d)Title of class of securities:

    Class A Common Stock
    (e)CUSIP No.:

    21217B100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Jerome G. Pfund: 950,786 shares Sectoral Asset Management Inc.: 800,787 shares
    (b)Percent of class:

    Jerome G. Pfund: 4.99 % Sectoral Asset Management Inc.: 4.2
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Jerome G. Pfund: 950,786shares Sectoral Asset Management Inc.: 800,787 shares Jerome G. Pfund in his capacity as the sole control person of Sectoral Asset Management Inc. and Sectoral Asset Management Limited has the sole right to vote the number of shares of Class A Common Stock of the Issuer set forth in this filing. Sectoral Asset Management Inc. has been included as a separate Reporting Person solely for administrative purposes to facilitate the filing process.

     (ii) Shared power to vote or to direct the vote:

    Not applicable

     (iii) Sole power to dispose or to direct the disposition of:

    Jerome G. Pfund: 950,786 shares Sectoral Asset Management Inc.: 800,787 shares Jerome G. Pfund in his capacity as the sole control person of Sectoral Asset Management Inc. and Sectoral Asset Management Limited has the sole right to dispose of the number of shares of Class A Common Stock of the Issuer set forth in this filing. Sectoral Asset Management Inc. has been included as a separate Reporting Person solely for administrative purposes to facilitate the filing process.

     (iv) Shared power to dispose or to direct the disposition of:

    Not applicable

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Various persons, as investment advisory clients of Sectoral Asset Management Inc. and Sectoral Asset Management Limited, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Class A Common Stock of the Issuer. However, no one such person's interest in the Class A Common Stock of the Issuer is more than five percent of the total outstanding common stock of the Issuer.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Sectoral Asset Management Inc
     
    Signature:/s/ Marina Lalakin
    Name/Title:Marina Lalakin/Chief Compliance Officer
    Date:02/14/2025
     
    Jerome G. Pfund
     
    Signature:/s/ Jerome G. Pfund
    Name/Title:Jerome G. Pfund
    Date:02/14/2025
    Get the next $CTNM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTNM

    DatePrice TargetRatingAnalyst
    10/22/2024$32.00Outperform
    Robert W. Baird
    More analyst ratings

    $CTNM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

      4/28/25 4:05:00 PM ET
      $CTNM
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. "We are excited to welcome Diego to our board," commented Eef Schimmelpennink, Contineum's Chairperson. "He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr.

      3/17/25 4:05:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18th at 12:30 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum's website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with s

      3/12/25 4:05:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CMO & Head of Development Watkins Tim

      4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      4/28/25 4:21:48 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Watkins Tim

      3 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      4/28/25 4:16:12 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Miralles Gines Diego

      4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      3/17/25 4:12:41 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Contineum Therapeutics Inc.

      SC 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)

      11/14/24 4:38:16 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Contineum Therapeutics with a new price target

      Robert W. Baird initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $32.00

      10/22/24 6:13:41 AM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Contineum Therapeutics Inc.

      DEFA14A - Contineum Therapeutics, Inc. (0001855175) (Filer)

      4/29/25 4:14:06 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Contineum Therapeutics Inc.

      DEF 14A - Contineum Therapeutics, Inc. (0001855175) (Filer)

      4/29/25 4:07:27 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Contineum Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)

      4/28/25 4:10:35 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Leadership Updates

    Live Leadership Updates

    See more
    • Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

      4/28/25 4:05:00 PM ET
      $CTNM
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. "We are excited to welcome Diego to our board," commented Eef Schimmelpennink, Contineum's Chairperson. "He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr.

      3/17/25 4:05:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

      SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe

      1/6/25 8:00:00 AM ET
      $CTNM
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care